New Horizon Capital is a top-tier private equity fund focused on investing in China.
Business Model:
Revenue: $26.2M
Employees: 201-500
Address: Room 1702-1703, Building 1, No. 8 Exchange Square
City: Hong Kong
State: other
Zip:
Country: HK
New Horizon Capital is a top-tier private equity fund focusing on investing in china. It was incorporated in Cayman Islands in May 2005 with two limited partners: Tamasek Holdings Private Limited and SBI Holdings Inc. They currently manage over approximately $2.5 billion RMB and USD funds. Their LPs include more than 20 internationally renowned institutions The Fund is managed by a group of highly professional and experienced staff who have very strong business sense to identify and capture various investment opportunities. The firm invests in companies in consumer &a; retail, alternative energy, pharmaceutical &a; healthcare and advanced manufacturing sectors. It makes investment either through purchase of non-tradable stocks of domestic listed company or equity interest in private company at expansion stage. China&s;s rapid economic growth in the context of the Fund&s;s investment and participation in the target company will bring rapid and stable development, to bring investors good returns and also benefit the local government, in order to achieve multi-win-win situation.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2016 | GoGoX | Series C | - |
9/2016 | Genetron Health | Series B | - |
7/2015 | Huitongda | Series A | 80.8M |
12/2015 | Wochu.cn | Series A | 1.5M |
5/2016 | Chuchujie | Series C | 153.9M |
12/2013 | Punch Powertrain | Private Equity Round | - |
4/2015 | Kakao | Series A | - |
10/2013 | Orbiepharm | Angel Round | 490.2k |
10/2016 | Xueleyun | Series C | 0 |
5/2015 | Bochewang | Series A | 16.2M |
1/2015 | BeiBei | Series C | 0 |
7/2017 | Qiagen Suzhou Translational Medicine | Series A | 0 |
7/2019 | Ke.com | Series D | 0 |
10/2016 | NeoBear | Series B | 37M |
6/2016 | BeiBei | Series D | 100M |
10/2013 | Chukong Technologies | Series D | 0 |
4/2014 | Arrail Dental Clinic | Series C | 70M |
8/2015 | HS Entertainment | Series B | 3.2M |
7/2021 | KK Group | Series F | 0 |
1/2015 | Zailushang | Series B | - |
5/2017 | Wacai.com | Series C | 0 |
7/2015 | Zhaolu Tianxia Wang | Series B | 3.2M |
7/2015 | Wacai.com | Series B | 80M |
10/2013 | Kuaidi Dache | Series B | 100M |
4/2015 | HuaKang Mobile Healthcare | Series B | 32M |
1/2016 | TalkingData | Series C | - |
11/2016 | Moviebook | Series C | - |
1/2014 | Wangxiangyuan | Series A | 19.6M |
4/2019 | Energy Monster | Series C | 0 |
7/2016 | Pinduoduo | Series B | 110M |
10/2016 | Xuele Zhongguo | Series C | 200M |
3/2015 | Yuanfudao | Series D | 60M |
7/2014 | Jinko Solar | Post-IPO Equity | 225M |
7/2021 | KK Group | Series F | 0 |
7/2019 | Ke.com | Series D | 0 |
4/2019 | Energy Monster | Series C | 0 |
7/2017 | Qiagen Suzhou Translational Medicine | Series A | 0 |
5/2017 | Wacai.com | Series C | 0 |
11/2016 | Moviebook | Series C | - |
10/2016 | NeoBear | Series B | 0 |
10/2016 | Xueleyun | Series C | 0 |
10/2016 | Xuele Zhongguo | Series C | 0 |
9/2016 | Genetron Health | Series B | - |
Name | Price |
---|
Name | Size | Announced Date |
---|